Disseminated Mycobacterium Sepsis with Bone Marrow, Liver, and Lung Involvement Following Intravesical Bacillus Calmette-Guerin (BCG) Therapy

Main Article Content

Drew Hager
Zeenib Kohja
Terry Wuerz
Arjuna Ponnampalam

Keywords

Disseminated BCG, histopathology

Abstract

Introduction: BCG therapy is first line therapy for high grade non-muscle invasive bladder cancer (NMIBC).

Case Presentation: A 54-year-old male presented with fevers, rigors and hematuria one week following intravesical BCG administration for treatment of NMIBC. He developed fever, pancytopenia, elevated liver enzymes and pulmonary infiltrates with progression of symptoms despite broad spectrum antimicrobial therapy. A bone marrow biopsy showed granulomatous infiltration; cultures of urine demonstrated growth of Mycobacterium bovis. A diagnosis of disseminated BCG infection secondary to intravesical administration was made; rifampin, isoniazid, ethambutol, and high dose prednisone were initiated.

Conclusion: Adverse events associated with BCG administration have been attributed to both the primary mycobacterium infection and to hypersensitivity reactions. Timely collection of histopathology can lead to early treatment of disseminated BCG with good outcomes. Internists should have a high index of suspicion for patients presenting with organ dysfunction with an immediate or remote history of intravesical BCG administration.
Abstract 47 | pdf Downloads 20 HTML Downloads 16

References

1. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015;99(October):9-10.

2. Sylvester RJ, van der Meijden APM, Witjes JA, et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):82-86.

3. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017. Available at: cancer.ca/Canadian-CancerStatistics-2017-EN.pdf.

4. Lamm DL. Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer. J Urol. 1992;147:596-600.

5. Lamm DL. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 2000;31(Supplement 3):S86-S90.

6. Macleod LC, Ngo TC, Gonzalgo ML. Complications of intravesical bacillus calmette-guerin. Can Urol Assoc J = J l’Association des Urol du Canada. 2014;8(7-8):E540-4.

7. Pérez-Jacoiste Asín MA, Fernandez-Ruiz M, Lopez-Medrano F, et al. Bacillus Calmette- Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014 Oct;93(17):236-54.

8. Board of Directors American Urological Association. Policy Statement: Intravesical Administration of Therapeutic Medication. July 2015. http://www.auanet.org/guidelines/intravesical-administration-of-therapeutic-medication.

9. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003;36(2):140-148.

10. DeHaven JI, Traynellis C, Riggs DR, et al. Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J Urol. 1992;147(3):738-742.

11. Gallivan M, Shah N, Flood J. Epidemiology of human mycobacterium bovis disease, California, USA, 2003–2011. Emerg Infect Dis. 2015;21(3):435-443.